儿童癌症GD2靶向药物开发战略论坛
GD2在神经母细胞瘤中高表达,也见于肉瘤和中枢神经系统肿瘤。第十四届ACCELERATE多利益相关方儿科战略论坛召开,旨在为靶向GD2的抗体及新型疗法(ADC、放射性药物、CAR-T、双特异性T细胞衔接器、疫苗)制定进一步开发策略,审查了7个工业界产品和学术界的GD2 CAR-T,并达成六项关键结论。
要点
- GD2表达定量标准化至关重要。
- 需对神经母细胞瘤一线单抗开展比较效果研究。
- 亟需快速筛选改善化学免疫治疗疗效的化合物。
核心结论
- GD2靶向治疗在神经母细胞瘤已成功,但需标准化表达定量并拓展至其他儿科肿瘤。
- 新型GD2疗法开发应整合一线治疗、开展比较效果研究并减轻毒性。
研究设计与样本
- 第十四届ACCELERATE多利益相关方儿科战略论坛,审查了7个工业界产品和学术界的GD2 CAR-T。
主要发现
- GD2在神经母细胞瘤中持续高表达,在肉瘤和中枢神经系统肿瘤中表达水平可变。
- GD2单抗已获批用于高危神经母细胞瘤一线巩固后和复发治疗,但非所有患者获益,且第一代抗体有剂量限制性神经病理性疼痛。
- 抗GD2抗体与化疗联合尚未获批,神经母细胞瘤以外的GD2靶向治疗探索有限。
临床怎么用
- 开发GD2靶向药物时需标准化GD2肿瘤表达定量。
- 神经母细胞瘤一线治疗应整合到新产品整体开发计划中。
- 开发中应早期与患者倡导者和监管机构互动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
GD2 is a ganglioside expressed on the cell surface of a wide range of paediatric cancers. Expression is most consistently seen at a high level in neuroblastoma, though sarcomas and central nervous system (CNS) cancers may express variable levels of GD2. GD2 has been successfully leveraged therapeutically for patients with high-risk neuroblastoma, for which GD2 monoclonal antibodies have regulatory approvals in the post-consolidation frontline and relapsed neuroblastoma settings. Not all patients benefit, and first-generation antibodies are associated with dose-limiting on-target / off-tumour neuropathic pain. More recently, anti-GD2 antibodies have been combined with chemotherapy for neuroblastoma, though none of these combinations has regulatory approval to date. The potential for targeting GD2 in paediatric cancers beyond neuroblastoma remains relatively unexplored. The 14th ACCELERATE multi-stakeholder Paediatric Strategy Forum was convened to define a strategy for further development of these antibodies, but also for emerging novel approaches leveraging GD2 as a tumour-associated antigen, including antibody-drug conjugates (ADC), radiopharmaceuticals, chimeric antigen receptor engineered T-cells (CAR-T), bispecific T-cell engagers, and vaccines. Seven products being developed by industry were reviewed along with GD2-directed CAR-Ts being developed by academia. Key conclusions included 1) the critical importance of standardisation in quantifying GD2 tumour expression; 2) need for ongoing innovation and comparative effectiveness research with monoclonal antibodies already used in the neuroblastoma frontline setting; 3) urgent need to rapidly screen compounds that may improve the efficacy of chemoimmunotherapy; 4) importance of integrating frontline therapy for neuroblastoma and other tumour types in overall development plans for novel products; 5) mitigation of neuropathic pain and other off-tumour toxicities remains a critical need; and 6) the value of early patient advocate and regulatory interactions during development.
引用
- DuBois SG, Moreno L, Bagatell R, et al. Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer. Eur J Cancer. 2025. PMID: 41240535. doi:10.1016/j.ejca.2025.116093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。